enGene Holdings Inc. (ENGN)
NASDAQ: ENGN · IEX Real-Time Price · USD
8.99
+0.04 (0.45%)
At close: Jul 19, 2024, 4:30 PM
9.01
+0.02 (0.22%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Company Description
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs.
Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
The company was founded in 2023 and is based in Saint-Laurent, Canada.
enGene Holdings Inc.
| Country | Canada |
| Founded | 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Jason D. Hanson Esq., J.D. |
Contact Details
Address: 4868 Rue Levy, Suite 220 Saint-laurent, A8 H4R 2P1 Quebec, Canada | |
| Phone | (514) 332-4888 |
| Website | engene.com |
Stock Details
| Ticker Symbol | ENGN |
| Exchange | NASDAQ |
| Fiscal Year | November - October |
| Reporting Currency | USD |
| CIK Code | 0001980845 |
| CUSIP Number | 46429B226 |
| ISIN Number | CA29286M1059 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jason D. Hanson Esq., J.D. | Chief Executive Officer and Director |
| Dr. Alex Nichols Ph.D. | President and Chief Operating Officer |
| Dr. James C. Sullivan M.Sc., Ph.D. | Chief Scientific Officer |
| Dr. Anthony T. Cheung Ph.D. | Co-Founder and Chief Technology Officer |
| John C. Brown D.Sc., FRSC, Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| David Ryan Daws | Chief Financial Officer and Head of Business Development |
| Lee G. Giguere | Chief Legal Officer and Corporate Secretary |
| Sharon Tan | Vice President of Project Management and Head of Program Management |
| Dr. Richard P. Bryce MBChB, MFPM, MRCGP | Chief Medical Officer |
| Paul Erickson | Non-Executive Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 14, 2024 | 424B3 | Prospectus |
| Jun 14, 2024 | 10-Q | Quarterly Report |
| Jun 14, 2024 | 8-K | Current Report |
| May 15, 2024 | 424B3 | Prospectus |
| May 15, 2024 | 8-K | Current Report |
| Apr 25, 2024 | 424B3 | Prospectus |
| Apr 18, 2024 | ARS | Filing |
| Apr 18, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 12, 2024 | 424B3 | Prospectus |
| Mar 11, 2024 | 10-Q | Quarterly Report |